https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-investor-call-azure-1-study BiopharmaWatch en 2026-09-27T21:00:00.000Z Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 https://www.biopharmawatch.com/news/ARAY/accuray-samsung-neurologica-collaboration-cyberknife BiopharmaWatch en 2026-09-27T15:15:00.000Z Accuray and Samsung NeuroLogica Advance Volumetric Imaging Collaboration for the Accuray CyberKnife® Platform https://www.biopharmawatch.com/news/ASTS/ast-spacemobile-securities-fraud-class-action BiopharmaWatch en 2026-09-26T15:33:00.000Z AST SpaceMobile, Inc. (NASDAQ: ASTS) Investors: November 13, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP https://www.biopharmawatch.com/news/MIRM/fda-approval-atebrioz-zilurgisertib-fop BiopharmaWatch en 2026-09-26T10:07:00.000Z Samenvatting: Mirum Pharmaceuticals en Incyte maken bekend dat de Amerikaanse FDA goedkeuring heeft verleend voor Atebrioz™ (zilurgisertib) voor volwassen en pediatrische patiënten met fibrodysplasia ossificans progressiva https://www.biopharmawatch.com/news/MIRM/riassunto-mirum-pharmaceuticals-e-incyte-annunciano-l-approvazione-da-parte BiopharmaWatch en 2026-09-26T10:07:00.000Z Riassunto: Mirum Pharmaceuticals e Incyte annunciano l’approvazione da parte dell’FDA statunitense di Atebrioz™ (zilurgisertib) per pazienti adulti e pediatrici affetti da fibrodisplasia ossificante progressiva (FOP) https://www.biopharmawatch.com/news/MIRM/mirum-incyte-fda-approval-zilurgisertib-fop BiopharmaWatch en 2026-09-26T10:06:00.000Z Resumen: Mirum Pharmaceuticals e Incyte anuncian que Atebrioz™ (zilurgisertib) obtuvo la aprobación de la FDA de los EE. UU. para pacientes adultos y pediátricos con fibrodisplasia osificante progresiva